Skip to main content
. Author manuscript; available in PMC: 2017 Aug 12.
Published in final edited form as: Sci Transl Med. 2017 Apr 12;9(385):eaak9679. doi: 10.1126/scitranslmed.aak9679

Fig. 4. Combined anti–PD-L1 and antiangiogenic therapy stimulates infiltration and activation of DCs and CTLs in responding tumors.

Fig. 4

(A) Immunofluorescence staining and quantitation of CD8+ and CD11c+ cells in RT2-PNET (IgG, n = 11; D 15W, n = 9; D + P 15W, n = 18; D 17W, n = 11; D + P, n = 13), MMTV-PyMT (IgG, D, P, and D + P, n = 20), and NFpp10-GBM (IgG, n = 18; B, n = 20; P, n = 13; B + P, n = 14) tumors. Quantitation of CD11c+ infiltrates is shown on the right. Scale bars, 25 μm. (B) qPCR-based expression analysis of FACS-sorted DCs in RT2-PNET (IgG, n = 4; D, n = 8; P, n = 8; D + P, n = 15 to 16), MMTV-PyMT (IgG, n = 4; D, n = 8; P, n = 11; D + P, n = 8), and NFpp10-GBM (IgG, n = 4; B, n = 8; P, n = 8; B + P, n = 8) tumors. (C) qPCR analysis of perforin in CD3+CD8+ CTLs from RT2-PNET (IgG, n = 4; D, n = 8; P, n = 8; D + P, n = 16), MMTV-PyMT (IgG, n = 6; D, n = 18; P, n = 12; D + P, n = 16), and NFpp10-GBM (IgG, n = 8; B, n = 24; P, n = 40; B + P, n = 32) tumors. Dotted line indicates baseline gene expression in IgG-treated samples. Data are presented as means ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001 (for exact P values, see table S2); Mann-Whitney test. Black asterisks represent P values for comparisons between IgG and different treatments; red asterisks represent P values for other comparisons.